TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11972943

Group type: EXPERIMENTAL
Intervention: ISDN at 128 kbit/s
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: ISDN at 384 kbit/s
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: ISDN at 768 kbit/s
Number of subjects: 4

Group type: COMPARATOR
Intervention: IP transmission
Number of subjects: 4
Study: 9633944

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d
Number of subjects: 63
Study: 7843010

Group type: EXPERIMENTAL
Intervention: Laser suture lysis following trabeculectomy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Trabeculectomy without laser suture lysis
Number of subjects: 45
Study: 2905287

Group type: EXPERIMENTAL
Intervention: 1 mg prostaglandin E2 in gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: gel only as placebo
Number of subjects: 40
Study: 28353070

Group type: EXPERIMENTAL
Intervention: AHA dietary counselling
Number of subjects: 119
Study: 29037226

Group type: EXPERIMENTAL
Intervention: Xingnaojing injection (XNJ) combined with standard care
Number of subjects: 720

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 720
Study: 26226139

Group type: EXPERIMENTAL
Intervention: Fish oil (4 g/d)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Corn oil (4 g/d)
Number of subjects: 80
Study: 24205023

Group type: EXPERIMENTAL
Intervention: Observation of hand actions
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Observation of foot actions
Number of subjects: 14
Study: 20846874

Group type: EXPERIMENTAL
Intervention: Total arterial revascularization
Number of subjects: 331

Group type: COMPARATOR
Intervention: Conventional coronary surgery
Number of subjects: 331
Study: 18427229

Group type: EXPERIMENTAL
Intervention: Active physical therapy (n=51)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (n=57)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Combination therapy (n=59)
Number of subjects: 167
Study: 16466838

Group type: EXPERIMENTAL
Intervention: Leftward moving visual stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left-sided moving visual stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-lateralised random moving visual stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: No stimulus condition
Number of subjects: 0
Study: 12847998

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 supplementation combined with multivitamins, selenium, and magnesium for six months
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 220
Study: 11304723

Group type: EXPERIMENTAL
Intervention: Cefadroxila 500 mg capsule
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cefamox 500 mg capsule
Number of subjects: 24
Study: 9207344

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (VAQTA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Immune globulin
Number of subjects: 70
Study: 8017402

Group type: EXPERIMENTAL
Intervention: Volunteer recruitment
Number of subjects: 3788

Group type: EXPERIMENTAL
Intervention: Population-based recruitment
Number of subjects: 3788

Group type: COMPARATOR
Intervention: Comparison of genders
Number of subjects: 3788

Group type: COMPARATOR
Intervention: General conclusions
Number of subjects: 3788
Study: 3415398

Group type: EXPERIMENTAL
Intervention: Duxil (30 mg almitrine and 10 mg raubasine, 1 tablet b.i.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (1 tablet b.i.d.)
Number of subjects: 12
Study: 31916828

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 12 weeks
Number of subjects: 119

Group type: COMPARATOR
Intervention: Waitlist control group for 16 weeks
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training followed by 4 weeks of deconditioning
Number of subjects: 119
Study: 31170944

Group type: EXPERIMENTAL
Intervention: Participatory workplace intervention aimed at improving psychosocial working environment, focusing on core job tasks.
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Participatory workplace intervention with high or medium degree of implementation.
Number of subjects: 606

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 606
Study: 28357460

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25238492

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/d
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg/day p.o
Number of subjects: 75

Group type: COMPARATOR
Intervention: Diclofenac sodium 50 mg p.o when required
Number of subjects: 75
Study: 22160300

Group type: EXPERIMENTAL
Intervention: Supplemental melatonin (1 or 3 mg dosages)
Number of subjects: 24
Study: 20949127

Group type: EXPERIMENTAL
Intervention: Random effects models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized estimating equations (GEE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster-level analyses treating the cluster as the unit of analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analyses that adjusted for the baseline response
Number of subjects: 0
Study: 18422051

Group type: EXPERIMENTAL
Intervention: FHF program (Fostering Healthy Futures)
Number of subjects: 0
Study: 16141271

Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (BH(4)) administration
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 12152004

Group type: EXPERIMENTAL
Intervention: Rofecoxib, 25 mg daily
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Celecoxib, 200 mg twice daily
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Naproxen, 500 mg twice daily
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 9514436

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7912878

Group type: EXPERIMENTAL
Intervention: 5 mg manidipine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 mg manidipine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2597953

Group type: EXPERIMENTAL
Intervention: Podophyllin (25% application)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Scissor excision
Number of subjects: 37
Study: 31504336

Group type: EXPERIMENTAL
Intervention: Intensive treatment (quarterly single-dose praziquantel, triple-dose albendazole)
Number of subjects: 1898

Group type: EXPERIMENTAL
Intervention: Schistosoma mansoni infection
Number of subjects: 1898

Group type: EXPERIMENTAL
Intervention: Strongyloides infection
Number of subjects: 1898

Group type: EXPERIMENTAL
Intervention: Moderate to heavy S. mansoni infection
Number of subjects: 1898
Study: 30325449

Group type: EXPERIMENTAL
Intervention: 100 mg of intravenous hydrocortisone followed by 0.5 mg of intravenous dexamethasone every 6 h for 4 doses (STER)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Surgery without steroids (NOSTER)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study: 28832978

Group type: COMPARATOR
Intervention: Bevacizumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg intravenously every 2 weeks plus TRC105 10 mg/kg intravenously every 2 weeks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Baseline serum TGFβ levels below the median (<10.6 ng/mL)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus TRC105
Number of subjects: 59
Study: 25183694

Group type: EXPERIMENTAL
Intervention: Intervention arm (received written and oral explanations on cardiac rehabilitation benefits and eligibility, and a follow-up telephone call 2 weeks after hospital discharge)
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Control arm (1-hour seminar to medical staff on the benefits of cardiac rehabilitation)
Number of subjects: 1024
Study: 23708389

Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal tablets
Number of subjects: 100

Group type: COMPARATOR
Intervention: Suction curettage
Number of subjects: 100
Study: 21564466

Group type: EXPERIMENTAL
Intervention: Deep Sedation (DS)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Moderate Sedation (MS)
Number of subjects: 520
Study: 18282319

Group type: EXPERIMENTAL
Intervention: BACS (Brief Assessment of Cognition in Schizophrenia)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Olanzapine, Quetiapine, Risperidone
Number of subjects: 367
Study: 16810760

Group type: EXPERIMENTAL
Intervention: Lamivudine treatment (n = 42)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lamivudine treatment
Number of subjects: 72
Study: 12707571

Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 0
Study: 10707786

Group type: EXPERIMENTAL
Intervention: PACEBOM
Number of subjects: 459

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 459
Study: 9085392

Group type: EXPERIMENTAL
Intervention: Enhanced screening program including a personalized educational booklet and motivational telephone call and diet-change program including nutrition classes, self-help materials, and computer-generated personalized feedback
Number of subjects: 5042

Group type: EXPERIMENTAL
Intervention: Enhanced screening program
Number of subjects: 5042

Group type: EXPERIMENTAL
Intervention: Diet-change program
Number of subjects: 5042

Group type: COMPARATOR
Intervention: Control group (company-sponsored screening program)
Number of subjects: 5042
Study: 1337607

Group type: EXPERIMENTAL
Intervention: Baclofen 5 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Baclofen 10 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Baclofen 15 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Naloxone (4 mg IV bolus plus 10 mg infused over 2 hr)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Baclofen (15 mg)
Number of subjects: 13
Study: 2863541

Group type: EXPERIMENTAL
Intervention: Warfarin for 3 months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-warfarin (control)
Number of subjects: 51
Study: 29986622

Group type: EXPERIMENTAL
Intervention: Endoscopic overlay tympanoplasty (EOT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Microscopic overlay tympanoplasty (MOT)
Number of subjects: 70
Study: 26730453

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA)
Number of subjects: 534

Group type: COMPARATOR
Intervention: Placebo/best supportive care (control)
Number of subjects: 534
Study: 24452810

Group type: EXPERIMENTAL
Intervention: Veliparib (ABT-888)
Number of subjects: 325
Study: 22212956

Group type: EXPERIMENTAL
Intervention: Bulimia nervosa (BN)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Eating Disorder Not Otherwise Specified BN-type (EDNOS-BN)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 82
Study: 19834474

Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss (aiming at reducing body weight by 10%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No intervention (subjects who did not reach the body-weight target)
Number of subjects: 20
Study: 18559041

Group type: EXPERIMENTAL
Intervention: FloSeal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ligatures
Number of subjects: 30
Study: 16286578

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1235

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 1235
Study: 11939912

Group type: EXPERIMENTAL
Intervention: dimenhydrinate
Number of subjects: 3045

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3045
Study: 10490723

Group type: EXPERIMENTAL
Intervention: G‐CSF started on day 0 (day 0 group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: G‐CSF started on day 5 (day 5 group)
Number of subjects: 60
Study: 9168671

Group type: COMPARATOR
Intervention: AgNORs counts in normal specimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AgNORs counts in mild dysplasia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AgNORs counts in moderate dysplasia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AgNORs counts in severe dysplasia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AgNORs counts in carcinoma in situ
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AgNORs counts in glandular extensions of carcinoma in situ
Number of subjects: 0
Study: 1748141

Group type: EXPERIMENTAL
Intervention: Org 10172 (bolus injection of 3250 anti‐Xa units)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg once daily for 8 days)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Org 10172 and Digoxin combination
Number of subjects: 6
Study: 6803946

Group type: EXPERIMENTAL
Intervention: Oral cholecystography
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Repeat oral cholecystography
Number of subjects: 25
Study: 30414822

Group type: EXPERIMENTAL
Intervention: 10-week instructor-led resistance training program
Number of subjects: 70
Study: 28720139

Group type: EXPERIMENTAL
Intervention: Combination of intramuscular/intra-articular prednisolone, methotrexate (MTX), and golimumab (GOL) for 24 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Combination of intramuscular/intra-articular prednisolone, methotrexate (MTX), and placebo for 24 weeks
Number of subjects: 88
Study: 26829760

Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage (MLD) treatments (5 sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60
Study: 24355210

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cediranib
Number of subjects: 0
Study: 21371166

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg·kg(‐1))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg·kg(‐1))
Number of subjects: 60
Study: 19098058

Group type: EXPERIMENTAL
Intervention: Immediate PCI
Number of subjects: 251

Group type: COMPARATOR
Intervention: Deferred PCI
Number of subjects: 251
Study: 17874530

Group type: EXPERIMENTAL
Intervention: Low-dose fixed combination of perindopril and indapamide
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Intensive gliclazide-MR-based regimen targeting HbA(1c) levels of 6.5% or less
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Standard therapy for blood glucose control
Number of subjects: 11140
Study: 14687174

Group type: EXPERIMENTAL
Intervention: Low-dose octreotide
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-dose octreotide
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Repetitive high-pressure mechanical sigmoid stimulation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Octreotide (during repetitive sigmoid stimulation)
Number of subjects: 15
Study: 11758266

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 42

Group type: COMPARATOR
Intervention: No anesthetic (Control group)
Number of subjects: 42
Study: 9223108

Group type: EXPERIMENTAL
Intervention: Stimulation with PMA
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Stimulation with H2O2
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Stimulation with FMLP
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Stimulation with GSH
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Stimulation with GM-CSF
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Stimulation with IL-2
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Stimulation with LPS
Number of subjects: 2

Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 2
Study: 7967758

Group type: EXPERIMENTAL
Intervention: Back-strengthening exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no exercise prescription)
Number of subjects: 60
Study: 3632149

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring program for digoxin
Number of subjects: 207

Group type: COMPARATOR
Intervention: Withdrawal of therapeutic drug monitoring program
Number of subjects: 207
Study: 30530584

Group type: EXPERIMENTAL
Intervention: In vitro maturation (IVM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: In vitro fertilisation (IVF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IVM and IVF
Number of subjects: 0
Study: 26644536

Group type: EXPERIMENTAL
Intervention: Cetuximab (CTX) 400 mg/m2 as loading dose followed by 250 mg/m2 once per week with radiotherapy (RT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cisplatin (CDDP) 40 mg/m2 once per week with radiotherapy (RT)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cetuximab (CTX) with radiotherapy (RT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cisplatin (CDDP) with radiotherapy (RT)
Number of subjects: 70
Study: 24549933

Group type: EXPERIMENTAL
Intervention: 13.3 mg/24 h rivastigmine patch
Number of subjects: 567

Group type: COMPARATOR
Intervention: 9.5 mg/24 h rivastigmine patch
Number of subjects: 567
Study: 23250170

Group type: EXPERIMENTAL
Intervention: Single bond total-etch adhesive (3M ESPE, USA)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: UniFil bond self-etch primer (GC, Tokyo, Japan)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Single bond total-etch adhesive (3M ESPE, USA) with blotting and primer application
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: UniFil bond with repriming treatment (UF-V and UF-VI)
Number of subjects: 77
Study: 20204691

Group type: EXPERIMENTAL
Intervention: Digestive enzyme supplementation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 17661864

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DEX) 30 mg tablets, administered preoperatively and three times in the first 24 hours post-surgery.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (P), administered following the same schedule as DEX.
Number of subjects: 100
Study: 16055276

Group type: EXPERIMENTAL
Intervention: GRACE tool
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nurse counseling
Number of subjects: 72
Study: 12373614

Group type: EXPERIMENTAL
Intervention: Rye bread high in phloem (HP, 14% of rye flour substituted with phloem powder)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rye bread low in phloem (LP, 7% of rye flour substituted with phloem powder)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo rye bread
Number of subjects: 75
Study: 9989683

Group type: EXPERIMENTAL
Intervention: High-oleate meal (50 g)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: High-palmitate meal (50 g)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Low-fat meal (15 g high-oleate oil)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Fasting FVIIc and FVIIa concentrations in RQ genotype
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Postprandial response in both RQ and RR genotypes
Number of subjects: 69
Study: 7582157

Group type: EXPERIMENTAL
Intervention: Local Intranasal Immunotherapy (LII) with macronized powder Parietaria officinalis pollen in increasing doses
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (5 patients)
Number of subjects: 20
Study: 2329484

Group type: EXPERIMENTAL
Intervention: Immersion technique
Number of subjects: 159

Group type: COMPARATOR
Intervention: Applanation technique
Number of subjects: 159

Group type: COMPARATOR
Intervention: Modified applanation technique
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Cataract patients
Number of subjects: 159

Group type: COMPARATOR
Intervention: Healthy young eyes
Number of subjects: 159
Study: 367655

Group type: EXPERIMENTAL
Intervention: Imipramine (10-20 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Scopolamine butylbromide (10-20 mg)
Number of subjects: 14
Study: 31786747

Group type: EXPERIMENTAL
Intervention: Self-setup of home respiratory polygraphy (HRP)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Nurse intervention for home respiratory polygraphy (HRP)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Self-setup of HRP
Number of subjects: 301

Group type: COMPARATOR
Intervention: Nurse setup of HRP
Number of subjects: 301
Study: 31711244

Group type: EXPERIMENTAL
Intervention: CD+PET/US
Number of subjects: 34

Group type: COMPARATOR
Intervention: CD only
Number of subjects: 34
Study: 27324724

Group type: EXPERIMENTAL
Intervention: Black tea tablet + standard treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 120
Study: 25262677

Group type: EXPERIMENTAL
Intervention: Water jet device containing chlorhexidine gel (Silonite®) for home use twice daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group with recommended oral hygiene measures without water jet usage
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study: 23592677

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Lifestyle Intervention (LI)
Number of subjects: 148
Study: 21908036

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg/day for 24 months
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo for 24 months
Number of subjects: 130
Study: 19264836

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine administered at 0, 6 and 14 weeks
Number of subjects: 74

Group type: COMPARATOR
Intervention: Hepatitis B vaccine administered at 6, 10 and 14 weeks
Number of subjects: 74
Study: 16174858

Group type: EXPERIMENTAL
Intervention: Estrogen-plus-progestin therapy (0.625 mg conjugated equine estrogens + 2.5 mg medroxyprogesterone acetate)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study: 11823394

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg with lidocaine 0.5% (3 mg.kg(‐1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isotonic saline (Control Group C)
Number of subjects: 30
Study: 10516413

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 100

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 100
Study: 7721498

Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isosorbide dinitrate 20 mg three times daily
Number of subjects: 30